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Human milk is recommended as the natural feeding for both term and preterm infants for the
several health benefits associated with its consumption. The importance of human milk is not only limited
to its nutritional value but it also includes the provision of bioactive factors involved in the optimization of
infants’ growth and neurodevelopment. A huge amount of researches indicates that the biological effects of
human milk are dose dependent. Moreover, an increasing number of studies are showing that breast milk
contains stem cells whose implications in infant neurodevelopment are under study. Hence, it is mandatory
to promote initiation of breastfeeding as well as to support its duration [1–4].
When taking into consideration feeding options for preterm infants, it should be highlighted that there
is a biological hierarchy with milk of own mothers’ being the first choice. When own mothers’ milk is not
available, donor human milk is recommended, whereas formula feeding should be the last choice [2].
Human milk feeding represents a cost-effective strategy to reduce disease impact and associated
costs in preterm infants, during the neonatal intensive care unit hospitalization [5]. Colaizy estimated
that suboptimal feeding of extremely low birth weight infants would cost $27.1 million (CI $24 million,
$30.4 million) in direct medical costs, $563,655 (CI $476,191, $599,069) in indirect nonmedical costs, and
$1.5 billion (CI $1.3 billion, $1.6 billion) in cost attributable to premature death [6].
The systematic review and meta-analysis published by Miller [7] summarized the available
evidence in relation to the dose-dependent effect of human milk feeding on decreasing morbidity in
infant born <28 weeks’ gestation and/or birth weight <1500 g. Recent studies have assessed the different
impact of human milk and preterm infant formula (PTF) feeding on one single outcome, thus limiting the
in-depth analysis of the synergic protective co-effects led by the different nutritional and non-nutritional
components of human milk against the most frequent comorbidities that affect premature infants.
Remarkably, Miller considered the combination of five major morbidities (necrotizing enterocolitis,
late onset sepsis, bronchopulmonary dysplasia, retinopathy of prematurity and neurodevelopment),
pointing out the clear protective effect of human milk against necrotizing enterocolitis and possible
reduction in late onset sepsis, severe retinopathy of prematurity and severe necrotizing enterocolitis.
The comparison between various combinations of mixed feeding, human milk and preterm infant
formula allowed for a specific investigation on the dose effect associated with human milk feeding.
However, no conclusive evidence has been drawn on the incidence of bronchopulmonary dysplasia
and on neurodevelopment, thus underlining the need for implementing research towards this direction.
This systematic review allows for gaining further insights on the importance of human milk to improve
the outcomes in preterm neonates. Within this context, it must be remembered that benefits of human milk
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include improvement of feeding tolerance, risk-reduction of re-hospitalization due to infectious diseases,
and neurodevelopment optimization. Thus, there is wide consensus in recognizing human milk feeding as a
cost-effective strategy in order to reduce economic costs related to prematurity and to aim to a personalized
therapy improving the quality of care in these infants [8]. These characteristics call for considering human
milk promotion and support in these vulnerable infants as a public health issue.
Human donor milk has been advocated as the first alternative in preterm infants when own mother’s
milk is not available. Even though it has been criticized for potentially being not cost effective, human donor
milk should be considered and implemented as a “bridge” to own mothers’ milk, in consideration of the
individual-specificity of human milk and of the importance of breastfeeding for the mother’s health [9].
In conclusion, health care professionals should be educated on the important role of human milk
in reducing the risk for developing comorbidities in preterm infants and should promote and protect
breastfeeding, supporting the mothers particularly in the first 14 days after delivery. Indeed, during
this window of time, the preterms’ mothers are at higher risk for producing an insufficient volume of
milk, thus experiencing the so called “impaired coming to volume”, which negatively affects the long
term lactation outcomes [10] in the broadest context possible. Future research on how tp implement
the starting and the duration of human milk feeding in preterm infants is needed.
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